When a person is diagnosed with schizophrenia, doctors look for ways to understand what is happening inside the brain. New research looks at a protein called GFAP. This protein is usually found in astrocytes, which are star-shaped cells that support and protect your brain's neurons.
Researchers looked at data from 854 people, including those with schizophrenia and healthy individuals. They found that levels of this protein were significantly higher in the blood of people with schizophrenia. Because this protein is released when these supporting cells are damaged, it could serve as a biological marker for the condition.
While these results are promising, the evidence is still early. The study noted several limitations, including high variety in how different studies were conducted and some potential bias in published reports. More research with larger groups of people is needed to fully understand what this protein means for daily care.
Common questions
What is GFAP and why does it matter?
GFAP is a protein found in astrocytes, which are star-shaped cells that support and protect your brain's neurons. When these cells are damaged, they release the protein into the blood. Finding higher levels of GFAP in people with schizophrenia suggests that these supporting cells may be experiencing damage.
Is this a new way to treat schizophrenia?
This research does not describe a new treatment. Instead, it looks at GFAP as a biomarker. A biomarker is a measurable sign of a condition. While it helps researchers understand the biology of schizophrenia better, it is not currently used as a replacement for standard medical care.
How certain are these findings?
The results show a significant link between higher GFAP levels and schizophrenia. However, the study noted high variation between different tests and some potential bias in reported data. Because of these factors, more large-scale studies are needed to confirm how useful this protein is for clinical use.
